- Hong Kong
- Healthcare Services
Chaoju Eye Care Holdings Full Year 2022 Earnings: Revenues Disappoint
Chaoju Eye Care Holdings (HKG:2219) Full Year 2022 Results
Key Financial Results
- Revenue: CN¥990.0m (flat on FY 2021).
- Net income: CN¥187.8m (up 16% from FY 2021).
- Profit margin: 19% (up from 16% in FY 2021).
- EPS: CN¥0.27 (up from CN¥0.26 in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Chaoju Eye Care Holdings Earnings Insights
Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare industry in Hong Kong.
Performance of the Hong Kong Healthcare industry.
The company's shares are up 4.5% from a week ago.
We should say that we've discovered 1 warning sign for Chaoju Eye Care Holdings that you should be aware of before investing here.
Valuation is complex, but we're helping make it simple.
Find out whether Chaoju Eye Care Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Chaoju Eye Care Holdings
Chaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China.
Undervalued with excellent balance sheet.